John M. Kaczmar

1.1k total citations
55 papers, 627 citations indexed

About

John M. Kaczmar is a scholar working on Oncology, Otorhinolaryngology and Surgery. According to data from OpenAlex, John M. Kaczmar has authored 55 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 23 papers in Otorhinolaryngology and 16 papers in Surgery. Recurrent topics in John M. Kaczmar's work include Cancer Immunotherapy and Biomarkers (23 papers), Head and Neck Cancer Studies (23 papers) and Lung Cancer Treatments and Mutations (11 papers). John M. Kaczmar is often cited by papers focused on Cancer Immunotherapy and Biomarkers (23 papers), Head and Neck Cancer Studies (23 papers) and Lung Cancer Treatments and Mutations (11 papers). John M. Kaczmar collaborates with scholars based in United States, Canada and United Kingdom. John M. Kaczmar's co-authors include Terry A. Day, Evan M. Graboyes, Anand K. Sharma, David M. Neskey, Shaun A. Nguyen, Hong Li, Mark A. Ellis, Chanita Hughes Halbert, Eric J. Lentsch and Flora Yan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

John M. Kaczmar

50 papers receiving 621 citations

Peers

Countries citing papers authored by John M. Kaczmar

Since Specialization

Citations

This map shows the geographic impact of John M. Kaczmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Kaczmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Kaczmar more than expected).

Fields of papers citing papers by John M. Kaczmar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Kaczmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Kaczmar. The network helps show where John M. Kaczmar may publish in the future.

Co-authorship network of co-authors of John M. Kaczmar

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Kaczmar. A scholar is included among the top collaborators of John M. Kaczmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Kaczmar. John M. Kaczmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors 2025 ·Clinical Cancer Research ·(unknown), Richard D. Carvajal, Paul K. Paik, Van K. Morris, Dan P. Zandberg, John M. Kaczmar, (unknown), (unknown), (unknown), (unknown), Patrick H. Lizotte, Elena V. Ivanova, Philippe L. Bédard, Glenn J. Hanna	0
2	Randomized Trial of Enhanced Versus Standard Navigation to Promote Timely Initiation of Adjuvant Radiotherapy for Head and Neck Cancer 2025 ·JCO Oncology Practice ·Evan M. Graboyes, (unknown), Katherine R. Sterba, Bhishamjit S. Chera, Emily Kistner‐Griffin, Elizabeth G. Hill, (unknown), Jason G. Newman, William G. Albergotti, Alexandra E. Kejner, Judith M. Skoner, Jennifer L. Harper, John M. Kaczmar, (unknown), Stephanie M. Zimmerman, Graham Warren, Anthony J. Alberg, Elizabeth A. Calhoun, Brian Nussenbaum, Chanita Hughes Halbert	2
3	Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma. 2024 ·Journal of Clinical Oncology ·Susanna V. Ulahannan, Thomas U. Marron, Haeseong Park, John M. Kaczmar, Ryan D. Stephenson, Nehal J. Lakhani, Greg Andrew Durm, Jaspreet Singh Grewal, Anthony B. El-Khoueiry, Jason J. Luke, Courtney Beers, Swaminathan Murugappan, Patricia LoRusso, Douglas R. Adkins, J. Randolph Hecht	2
4	The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers. 2024 ·Journal of Clinical Oncology ·Scott A. Roof, Glenn J. Hanna, Eleni M. Rettig, David M. Routman, F. Christopher Holsinger, Noah S. Kalman, Aarti Bhatia, Mihir R. Patel, James Jabalee, Sue S. Yom, Sujith Baliga, Adam Raben, John R. Sims, John M. Kaczmar, Mihir K. Bhayani, Barry M. Berger, Catherine Del Vecchio Fitz	1
5	Efficacy of a Navigation-Based Intervention vs Usual Care for Decreasing Delays in Starting Guideline-Adherent Adjuvant Therapy for Patients with Head and Neck Cancer 2024 ·International Journal of Radiation OncologyBiologyPhysics ·Evan M. Graboyes, Elizabeth G. Hill, Katherine R. Sterba, Bhishamjit S. Chera, (unknown), Emily Kistner‐Griffin, J. A. McCay, Jason G. Newman, William G. Albergotti, Alexandra E. Kejner, (unknown), Jennifer L. Harper, John M. Kaczmar, Stephanie M. Zimmerman, Graham Warren, Anthony J. Alberg, Elizabeth A. Calhoun, Brian Nussenbaum, (unknown)	1
6	A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study. 2024 ·Journal of Clinical Oncology ·Alexander T. Pearson, Tanguy Y. Seiwert, Roger B. Cohen, Nabil F. Saba, John M. Kaczmar, Mary J. Fidler, James L. Wade, Enrico Castellucci, Theodore Karrison, Rohan Katipally, Aditya Juloori, Ari J. Rosenberg, Daniel J. Haraf, Nishant Agrawal, Everett E. Vokes	4
7	879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) 2024 ·Annals of Oncology ·Jessica Weiss, John M. Kaczmar, Kevin J. Harrington, Rukmankesh Mehra, Frank Worden, (unknown), Anil K. Giri, Hyunseok Kang, (unknown), (unknown), Ammar Sukari, Clíona Grant, (unknown), Simon W. Jones, (unknown), Katharine A. Price	5
8	922P Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma 2023 ·Annals of Oncology ·Glenn J. Hanna, John M. Kaczmar, Dan P. Zandberg, Deborah Jean Lee Wong, Emrullah Yilmaz, Eric J. Sherman, (unknown), Assuntina G. Sacco, David F. Bohr, (unknown), Sanela Bilic, Rachel Salazar, (unknown), Christine H. Chung	3
9	Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer 2023 ·Journal of Clinical Oncology ·Julie E. Bauman, Nabil F. Saba, Denise J. Roe, Jessica R. Bauman, John M. Kaczmar, Aarti Bhatia, Jameel Muzaffar, Ricklie Julian, Steven Wang, (unknown), (unknown), Conor Steuer, (unknown), Barbara Burtness, Sara Centuori, Carlos Caulı́n, Robert J. Klein, Kathylynn Saboda, (unknown), Christine H. Chung	25
10	Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC). 2023 ·Journal of Clinical Oncology ·(unknown), John M. Kaczmar, Brian Riesenberg, Carolyn D. Britten, (unknown), Elizabeth G. Hill, (unknown), Zihai Li	0
11	Anatomic Region of Cutaneous Melanoma Impacts Survival and Clinical Outcomes: A Population-Based Analysis 2023 ·Cancers ·(unknown), Neil K. Mehta, Hong Li, Shaun A. Nguyen, Sina Koochakzadeh, Dirk M. Elston, John M. Kaczmar, Terry A. Day	15
12	924P Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) 2023 ·Annals of Oncology ·Kevin J. Harrington, (unknown), Katharine A. Price, John M. Kaczmar, (unknown), (unknown), Sarah Jones, (unknown), (unknown), (unknown)	3
13	Systematic review of neuroendocrine carcinomas of the oropharynx 2022 ·Head & Neck ·(unknown), (unknown), (unknown), Anvesh Kompelli, (unknown), Shaun A. Nguyen, John M. Kaczmar, Cherie‐Ann O. Nathan, Terry A. Day, David M. Neskey	2
14	731MO A phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors 2022 ·Annals of Oncology ·(unknown), (unknown), Van K. Morris, Richard D. Carvajal, Paul K. Paik, Dan P. Zandberg, John M. Kaczmar, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Philippe L. Bédard	1
15	Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck Cancer 2021 ·JCO Oncology Practice ·Evan M. Graboyes, Katherine R. Sterba, Hong Li, Graham Warren, Anthony J. Alberg, Elizabeth A. Calhoun, Brian Nussenbaum, (unknown), (unknown), Nosayaba Osazuwa‐Peters, David M. Neskey, John M. Kaczmar, Anand K. Sharma, Jennifer L. Harper, Terry A. Day, Chanita Hughes Halbert	26
16	Microscopic Extranodal Extension in HPV‐Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation 2021 ·Otolaryngology ·Flora Yan, Hong Li, John R. de Almeida, John M. Kaczmar, Patrik Pipkorn, Joseph Zenga, Mary S. Richardson, David M. Neskey, Anand K. Sharma, Terry A. Day, Evan M. Graboyes	5
17	The Evolution of Care of Cancers of the Head and Neck Region: State of the Science in 2020 2020 ·Cancers ·Flora Yan, Hannah M. Knochelmann, (unknown), John M. Kaczmar, David M. Neskey, Evan M. Graboyes, Shaun A. Nguyen, Besim Öğretmen, Anand K. Sharma, Terry A. Day	26
18	71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results 2020 ·Annals of Oncology ·Dan P. Zandberg, Robert L. Ferris, Douglas Laux, Ranee Mehra, Lisle M. Nabell, John M. Kaczmar, Michael K. Gibson, (unknown), (unknown), Julie E. Bauman, Ricklie Julian, Douglas R. Adkins, Ezra E.W. Cohen, Barbara Burtness, (unknown), (unknown), (unknown), Angela Loi, (unknown), Nabil F. Saba	23
19	Hobnail variant of papillary thyroid carcinoma: a systematic review and meta-analysis 2020 ·Endocrine ·(unknown), Flora Yan, (unknown), John M. Kaczmar, Jyotika K. Fernandes, Shaun A. Nguyen, (unknown), Terry A. Day	25
20	Racial and Ethnic Disparities in Travel for Head and Neck Cancer Treatment and the Impact of Travel Distance on Survival 2018 ·Cancer ·Evan M. Graboyes, Mark A. Ellis, Hong Li, John M. Kaczmar, Anand K. Sharma, Eric J. Lentsch, Terry A. Day, Chanita Hughes Halbert	55

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact